Preliminary results of metabolite in serum and urine of lung cancer patients detected by metabolomics

Chinese Journal of Lung Cancer

Volumn 15, Issue 4, 2012, Pages 195-201

  Niu, Yanjie ^a   Jiang, Yinling ^a   Xu, Changjiang ^b   Wang, Xiangying ^a   Liu, Youru ^a   Zhao, Heng ^a   Han, Baohui ^a   Jiang, Liyan ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

^b Department of Rehabilitation Medicine   (China)

Author keywords

Biological markers; Diagnosis; Gas chromatography Mass spectrometry; Lung neoplasms; Metabolomics

Indexed keywords

TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; HUMAN; LUNG CANCER; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOMICS; MOLECULAR WEIGHT; SERUM; URINALYSIS;

EID: 84990002815     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.04.01     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90.
2. Chen WQ, Zhang SW, Zou XN. Estimation and projection of lung cancer incidence and mortality in China. Zhongguo Fei Ai Za Zhi, 2010, 13(5): 488-493.
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2007, 2(8): 706-714.
4. Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov, 2002, 1(2): 153-161.
5. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer, 2004, 4(7): 551-561.
6. Bathen TF, Jensen LR, Sitter B, et al. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat, 2007, 104(2): 181-189.
7. Odunsi K, Wollman RM, Ambrosone CB, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer, 2005, 113(5): 782-788.
8. Abate-Shen C, Shen MM. Diagnostics: The prostate-cancer metabolome. Nature, 2009, 457(7231): 799-800.
9. Bharti A, Ma PC, Salgia R. Biomarker discovery in lung cancer--promises and challenges of clinical proteomics. Mass Spectrom Rev, 2007, 26(3): 451-466.
10. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem, 2006, 42: 1-41.
11. Garcia A, Barbas C. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics. Methods Mol Biol, 2011, 708: 191-204.
12. Chen Z, Lu W, Garcia-Prieto C, et al. The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr, 2007, 39(3): 267-274.
13. Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med, 2006, 55(6): 1257-1264.
14. Tessem MB, Swanson MG, Keshari KR, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med, 2008, 60(3): 510-516.
15. Griffin JL, Kauppinen RA. A metabolomics perspective of human brain tumours. FEBS J, 2007, 274(5): 1132-1139.
16. Chen JH, Enloe BM, Fletcher CD, et al. Biochemical analysis using highresolution magic angle spinning NMR spectroscopy distinguishes lipomalike well-differentiated liposarcoma from normal fat. J Am Chem Soc, 2001, 123(37): 9200-9201.
17. Tomlins AM, Foxall PJD, Lindon JC, et al. High resolution magic angle spinning 1H nuclear magnetic resonance analysis of intact prostatic hyperplastic and tumor tissues. Anal Commun, 1998, 35: 113-115.
18. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q, 1994, 10(4): 191-247.